Prothena (NASDAQ:PRTA - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.
Other research analysts have also issued reports about the company. Chardan Capital restated a "buy" rating and set a $18.00 price target on shares of Prothena in a research report on Thursday, August 28th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Prothena in a report on Friday, June 20th. Royal Bank Of Canada decreased their target price on Prothena from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Tuesday, August 5th. HC Wainwright lifted their target price on Prothena from $14.00 to $20.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Piper Sandler decreased their target price on Prothena from $81.00 to $15.00 and set an "overweight" rating for the company in a report on Thursday, August 28th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $20.50.
Check Out Our Latest Stock Report on Prothena
Prothena Stock Up 1.8%
PRTA stock opened at $10.35 on Wednesday. The business has a fifty day moving average of $8.47 and a two-hundred day moving average of $7.95. The stock has a market cap of $557.14 million, a price-to-earnings ratio of -1.84 and a beta of -0.11. Prothena has a 52-week low of $4.32 and a 52-week high of $18.88.
Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.75). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.The firm had revenue of $4.42 million for the quarter, compared to analysts' expectations of $5.36 million. As a group, sell-side analysts anticipate that Prothena will post -4.04 EPS for the current year.
Institutional Investors Weigh In On Prothena
Institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its holdings in Prothena by 4,626.0% in the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 5,875 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in Prothena in the 2nd quarter valued at approximately $61,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Prothena in the 1st quarter valued at approximately $126,000. Tower Research Capital LLC TRC boosted its holdings in Prothena by 571.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,709 shares of the biotechnology company's stock valued at $77,000 after purchasing an additional 10,815 shares in the last quarter. Finally, Corton Capital Inc. purchased a new stake in Prothena in the 2nd quarter valued at approximately $85,000. Hedge funds and other institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.